Skip to main content

Articles

Page 33 of 38

  1. Acute myeloid leukemia (AML) is a heterogeneous disorder with aberrant regulation of a variety of signal pathways. Therefore, simultaneous targeting of two or even more deregulated signal transduction pathways...

    Authors: Haitao Meng, Yingming Jin, Hui Liu, Liangshun You, Chunmei Yang, Xue Yang and Wenbin Qian
    Citation: Journal of Hematology & Oncology 2013 6:18
  2. Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet ag...

    Authors: Ted Wun, Denis Soulieres, Andrew L Frelinger, Lakshmanan Krishnamurti, Enrico M Novelli, Abdullah Kutlar, Kenneth I Ataga, Charles L Knupp, Lillian E McMahon, John J Strouse, Chunmei Zhou, Lori E Heath, Chuke E Nwachuku, Joseph A Jakubowski, Jeffrey S Riesmeyer and Kenneth J Winters
    Citation: Journal of Hematology & Oncology 2013 6:17
  3. We conducted a prospective, randomized, open-label, multicenter study to compare busulfan plus fludarabine (BuFlu) with busulfan plus cyclophosphamide (BuCy) as the conditioning regimen in allogeneic hematopoi...

    Authors: Hui Liu, Xiao Zhai, Zhaoyang Song, Jing Sun, Yang Xiao, Danian Nie, Yu Zhang, Fen Huang, Hongsheng Zhou, Zhiping Fan, Sanfang Tu, Yonghua Li, Xutao Guo, Guopan Yu and Qifa Liu
    Citation: Journal of Hematology & Oncology 2013 6:15
  4. Allogeneic hematopoietic stem cell transplantation (HSCT) for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is much more intensive tha...

    Authors: Koji Nagafuji, Toshihiro Miyamoto, Tetsuya Eto, Tomohiko Kamimura, Shuichi Taniguchi, Takashi Okamura, Eiichi Ohtsuka, Takashi Yoshida, Masakazu Higuchi, Goichi Yoshimoto, Tomoaki Fujisaki, Yasunobu Abe, Yasushi Takamatsu, Shouhei Yokota, Koichi Akashi and Mine Harada
    Citation: Journal of Hematology & Oncology 2013 6:14
  5. The symptom burden associated with multiple myeloma (MM) is often severe. Presently, no instrument comprehensively assesses disease-related and treatment-related symptoms in patients with MM. We sought to vali...

    Authors: Desiree Jones, Elisabeth G Vichaya, Xin Shelley Wang, Loretta A Williams, Nina D Shah, Sheeba K Thomas, Valen E Johnson, Richard E Champlin, Charles S Cleeland and Tito R Mendoza
    Citation: Journal of Hematology & Oncology 2013 6:13
  6. The human c-mpl gene (MPL) plays an important role in the development of megakaryocytes and platelets as well as the self-renewal of haematopoietic stem cells. However, numerous MPL mutations have been identified...

    Authors: Xin He, Zhigang Chen, Yangyan Jiang, Xi Qiu and Xiaoying Zhao
    Citation: Journal of Hematology & Oncology 2013 6:11
  7. We investigated the utility of bioluminescence imaging (BLI) using firefly luciferase in monoclonal and polyclonal populations of leukemia cells in vitro and in vivo.

    Authors: Sandra Christoph, Jennifer Schlegel, Francesca Alvarez-Calderon, Yong-Mi Kim, Luis N Brandao, Deborah DeRyckere and Douglas K Graham
    Citation: Journal of Hematology & Oncology 2013 6:10
  8. Interactions between genetic variants and risk factors in myelodysplastic syndromes are poorly understood. In this case–control study, we analyzed 1 421 single nucleotide polymorphisms in 408 genes involved in...

    Authors: Monika Belickova, Michaela Dostalova Merkerova, Eliska Stara, Jitka Vesela, Dana Sponerova, Dana Mikulenkova, Radim Brdicka, Radana Neuwirtova, Anna Jonasova and Jaroslav Cermak
    Citation: Journal of Hematology & Oncology 2013 6:9
  9. Previous studies demonstrated that selenite induced cancer-cell apoptosis through multiple mechanisms; however, effects of selenite on microtubules in leukemic cells have not been demonstrated.

    Authors: Kejian Shi, Qian Jiang, Zhushi Li, Lei Shan, Feng Li, JiaJia An, Yang Yang and Caimin Xu
    Citation: Journal of Hematology & Oncology 2013 6:7
  10. MicroRNAs (miRNAs) are emerging as a novel class of non-coding RNA molecules that regulate gene expression at a post-transcriptional level. More than 1000 miRNAs have been identified in human cells to date, an...

    Authors: Yu-Meng Sun, Kang-Yu Lin and Yue-Qin Chen
    Citation: Journal of Hematology & Oncology 2013 6:6
  11. Tissue factor (TF) pathway inhibitor-1 (TFPI) is expressed in several malignant tissues- and cell lines and we recently reported that it possesses anti-tumor effects in breast cancer cells, indicating a biolog...

    Authors: Benedicte Stavik, Mari Tinholt, Marit Sletten, Grethe Skretting, Per Morten Sandset and Nina Iversen
    Citation: Journal of Hematology & Oncology 2013 6:5
  12. To assess if intensity-modulated radiotherapy (IMRT) can possibly lead to improved local control and lower incidence of vision impairment/blindness in comparison to non-IMRT techniques when treating sinonasal ...

    Authors: Alexander Chi, Nam P Nguyen, William Tse, Gill Sobremonte, Patrick Concannon and Angela Zhu
    Citation: Journal of Hematology & Oncology 2013 6:4
  13. Notch1 is a potent regulator known to play an oncogenic role in many malignancies including T-cell acute lymphoblastic leukemia (T-ALL). Tumor hypoxia and increased hypoxia-inducible factor-1α (HIF-1α) activit...

    Authors: Jie Zou, Peng Li, Fei Lu, Na Liu, Jianjian Dai, Jingjing Ye, Xun Qu, Xiulian Sun, Daoxin Ma, Jino Park and Chunyan Ji
    Citation: Journal of Hematology & Oncology 2013 6:3
  14. Despite advances in understanding of clinical, genetic, and molecular aspects of multiple myeloma (MM) and availability of more effective therapies, MM remains incurable. The autologous-allogeneic (auto-allo) ...

    Authors: Mohamed A Kharfan-Dabaja, Mehdi Hamadani, Tea Reljic, Taiga Nishihori, William Bensinger, Benjamin Djulbegovic and Ambuj Kumar
    Citation: Journal of Hematology & Oncology 2013 6:2
  15. Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white...

    Authors: James D Mellor, Michael P Brown, Helen R Irving, John R Zalcberg and Alexander Dobrovic
    Citation: Journal of Hematology & Oncology 2013 6:1
  16. A previous study has demonstrated a significant decrease in the TCRζ gene expression level in chronic myeloid leukemia (CML); thus, we further investigated the expression of TCRζ-regulating factors, the distri...

    Authors: Xianfeng Zha, Xiaojuan Yan, Qi Shen, Yuping Zhang, Xiuli Wu, Shaohua Chen, Bo Li, Lijian Yang, Suxia Geng, Jianyu Weng, Xin Du and Yangqiu Li
    Citation: Journal of Hematology & Oncology 2012 5:74
  17. Stem cell factor (SCF) activates hematopoietic stem cell (HSC) self-renewal and is being used to stimulate the ex vivo expansion of HSCs. The mechanism by which SCF supports expansion of HSCs remains poorly un...

    Authors: Jie Fan, Xinxin Ding and Yongping Jiang
    Citation: Journal of Hematology & Oncology 2012 5:73
  18. Lenalidomide treatment in myelodysplastic syndrome (MDS) may lead to thrombocytopenia and dose reductions/delays. This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and ...

    Authors: Eunice S Wang, Roger M Lyons, Richard A Larson, Sunil Gandhi, Delong Liu, Carmen Matei, Bart Scott, Kuolung Hu and Allen S Yang
    Citation: Journal of Hematology & Oncology 2012 5:71
  19. Promotion of endothelial normalization restores tumor oxygenation and obstructs tumor cells invasion, intravasation, and metastasis. We therefore investigated whether a vasoactive drug, tanshinone IIA, could i...

    Authors: Wen-Quan Wang, Liang Liu, Hui-Chuan Sun, Yan-Ling Fu, Hua-Xiang Xu, Zong-Tao Chai, Qiang-Bo Zhang, Ling-Qun Kong, Xiao-Dong Zhu, Lu Lu, Zheng-Gang Ren and Zhao-You Tang
    Citation: Journal of Hematology & Oncology 2012 5:69
  20. Pancreatic cancer (PC) is a lethal malignancy primarily driven by activated Kras mutations and characterized by the deregulation of several genes including mucins. Previous studies on mucins have identified their...

    Authors: Satyanarayana Rachagani, María P Torres, Sushil Kumar, Dhanya Haridas, Michael Baine, Muzafar A Macha, Sukhwinder Kaur, Moorthy P Ponnusamy, Parama Dey, Parthasarathy Seshacharyulu, Sonny L Johansson, Maneesh Jain, Kay-Uwe Wagner and Surinder K Batra
    Citation: Journal of Hematology & Oncology 2012 5:68
  21. The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituxi...

    Authors: Pier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, Bernardo Garicochea, Jan Walewski, Achiel Van Hoof, Pierre Soubeyran, Dolores Caballero, Rena Buckstein, Dixie-Lee Esseltine, Panteli Theocharous, Christopher Enny, Eugene Zhu, Yusri A Elsayed and Bertrand Coiffier
    Citation: Journal of Hematology & Oncology 2012 5:67
  22. The discovery of miRNAs has revolutionized the way we examine the genome, RNA products, and the regulation of transcription and translation. Their ability to modulate protein expression through mRNA degradatio...

    Authors: Anthony Virtue, Hong Wang and Xiao-feng Yang
    Citation: Journal of Hematology & Oncology 2012 5:66
  23. von Willebrand factor (vWF) is a multimeric glycoprotein essential for hemostasis after vascular injury, which modulates platelet-surface and platelet–platelet interactions by linking platelet receptors to the...

    Authors: Hailong Yuan, Ning Deng, Songmei Zhang, Yange Cao, Qiong Wang, Xin Liu and Qing Zhang
    Citation: Journal of Hematology & Oncology 2012 5:65
  24. Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standar...

    Authors: Shundong Cang, Nikhil Mukhi, Kemeng Wang and Delong Liu
    Citation: Journal of Hematology & Oncology 2012 5:64
  25. In the first line treatment of non-small cell lung cancer (NSCLC), several clinical trials have shown that not all NSCLC patients can benefit from treatment with tyrosine kinase inhibitors (TKIs) than receivin...

    Authors: Chongrui Xu, Qing Zhou and Yi-long Wu
    Citation: Journal of Hematology & Oncology 2012 5:62
  26. The recent findings brought the necessity of testing the mutational status of a series of genes which had been already identified as responsible for melanomas development and progression, such as BRAF, CKIT an...

    Authors: Giovanni Ponti, Aldo Tomasi and Giovanni Pellacani
    Citation: Journal of Hematology & Oncology 2012 5:60
  27. Patients with many types of autoimmune diseases (AIDs) are at an increased risk of cancer, which may depend on underlying dysregulation of the immune system or treatment. We systematically analyzed myeloma ris...

    Authors: Kari Hemminki, Xiangdong Liu, Asta Försti, Jianguang Ji, Jan Sundquist and Kristina Sundquist
    Citation: Journal of Hematology & Oncology 2012 5:59
  28. Colorectal Cancer (CRC) is one of the leading causes of death worldwide. Numerous cellular events, including deregulated expression of microRNAs (miRNAs), specifically the family of miR-34 consisting of miR-34...

    Authors: Sanchita Roy, Edi Levi, Adhip PN Majumdar and Fazlul H Sarkar
    Citation: Journal of Hematology & Oncology 2012 5:58
  29. Lymphomas frequently retain wild-type (wt) p53 function but overexpress HDM2, thereby compromising p53 activity. Therefore, lymphoma is a suitable model for studying the therapeutic value of disrupting the HDM...

    Authors: Angela M Sosin, Angelika M Burger, Aisha Siddiqi, Judith Abrams, Ramzi M Mohammad and Ayad M Al-Katib
    Citation: Journal of Hematology & Oncology 2012 5:57
  30. Recent studies have been reported that angiogenesis suppression may play a role in developing bisphosphonate-related osteonecrosis of the jaw (B-ONJ). According to these evidence we evaluated the role of VEGF ...

    Authors: Bruno Vincenzi, Andrea Napolitano, Alice Zoccoli, Michele Iuliani, Francesco Pantano, Nicola Papapietro, Vincenzo Denaro, Daniele Santini and Giuseppe Tonini
    Citation: Journal of Hematology & Oncology 2012 5:56
  31. Despite the combinations of chemotherapy with monoclonal antibodies have further improved response rates, chronic lymphocytic leukemia (CLL) remains an incurable disease with an extremely variable course. This...

    Authors: Kang Lu and Xin Wang
    Citation: Journal of Hematology & Oncology 2012 5:55
  32. Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin Lymphoma comprising of greater than 30% of adult non-Hodgkin Lymphomas. DLBCL represents a diverse set of lymphomas, defined as diff...

    Authors: Carlos A Tirado, Weina Chen, Rolando García, Kelly A Kohlman and Nagesh Rao
    Citation: Journal of Hematology & Oncology 2012 5:54
  33. Arsenic Trioxide (ATO) is effective in about 20% of patients with myelodysplasia (MDS); its mechanisms of action have already been evaluated in vitro, but the in vivo activity is still not fully understood. Si...

    Authors: Sara Galimberti, Francesca Guerrini, Flavia Salvi, Iacopo Petrini, Daniela Gioia, Emanuela Messa, Giuseppe A Palumbo, Daniela Cilloni, Mario Petrini and Alessandro Levis
    Citation: Journal of Hematology & Oncology 2012 5:53
  34. Epidermal growth factor receptor gene copy number (EGFR GCN) has been heavily investigated as a potential predictive biomarker for the treatment of metastatic colorectal cancer (mCRC) with anti-EGFR monoclonal an...

    Authors: Zu-Yao Yang, Wei-Xi Shen, Xue-Feng Hu, Da-Yong Zheng, Xin-Yin Wu, Ya-Fang Huang, Jin-Zhang Chen, Chen Mao and Jin-Ling Tang
    Citation: Journal of Hematology & Oncology 2012 5:52
  35. The precise mechanism of action for rituximab (R) is not fully elucidated. Besides antibody-dependent cellular cytotoxicity (ADCC), complements may also play an important role in the clinical response to ritux...

    Authors: Xuan Jin, Huirong Ding, Ning Ding, Zhiying Fu, Yuqin Song and Jun Zhu
    Citation: Journal of Hematology & Oncology 2012 5:51
  36. The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland.

    Authors: Yu Ri Kim, Jin Seok Kim, Yoo Hong Min, Dok Hyun Yoon, Ho-Jin Shin, Yeung-Chul Mun, Yong Park, Young Rok Do, Seong Hyun Jeong, Joon Seong Park, Sung Yong Oh, Suee Lee, Eun Kyung Park, Joung-Soon Jang, Won-Sik Lee, Hwe-Won Lee…
    Citation: Journal of Hematology & Oncology 2012 5:49
  37. The molecular pathogenesis underlying the primary myelofibrosis (PMF) progression to acute myeloid leukemia (AML) is still not well defined. The involvement of microRNA (miRNA) is actually helping to shed ligh...

    Authors: Francesco Albano, Luisa Anelli, Antonella Zagaria, Nicoletta Coccaro, Paola Casieri, Angela Minervini and Giorgina Specchia
    Citation: Journal of Hematology & Oncology 2012 5:48
  38. The mechanisms responsible for chemoresistance in patients with refractory classical Hodgkin lymphoma (CHL) are unknown. ATP-binding cassette (ABC) transporters confer multidrug resistance in various cancers and

    Authors: Wesley Greaves, Lianchun Xiao, Beatriz Sanchez-Espiridion, Kranthi Kunkalla, Kunal S Dave, Cynthia S Liang, Rajesh R Singh, Anas Younes, L Jeffrey Medeiros and Francisco Vega
    Citation: Journal of Hematology & Oncology 2012 5:47
  39. Intensified conditioning regimens (increasing the intensity of standard myeloablative conditioning) for hematological malignancies in allogeneic hematopoietic stem cell transplantation (allo-HSCT) could reduce...

    Authors: Li Xuan, Fen Huang, Zhiping Fan, Hongsheng Zhou, Xian Zhang, Guopan Yu, Yu Zhang, Can Liu, Jing Sun and Qifa Liu
    Citation: Journal of Hematology & Oncology 2012 5:46
  40. Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including hig...

    Authors: Luana Fianchi, Marianna Criscuolo, Monia Lunghi, Gianluca Gaidano, Massimo Breccia, Alessandro Levis, Carlo Finelli, Valeria Santini, Pellegrino Musto, Esther N Oliva, Pietro Leoni, Antonietta Aloe Spiriti, Francesco D’Alò, Stefan Hohaus, Livio Pagano, Giuseppe Leone…
    Citation: Journal of Hematology & Oncology 2012 5:44
  41. Splenomegaly is a common sign of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), and post-essential thrombocythemia myelofibrosis (post-ET MF) that is associated with bothersome...

    Authors: Jasleen Randhawa, Alen Ostojic, Radovan Vrhovac, Ehab Atallah and Srdan Verstovsek
    Citation: Journal of Hematology & Oncology 2012 5:43

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here